This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1. RC Kessler , P Berglund , O Demler , . The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23): 3095–3105.
2. PE Greenberg , RC Kessler , HG Birnbaum , . The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003; 64(12): 1465–1475.
3. JP Ioannidis . Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? Philos Ethics Humanit Med. 2008; 3: 14.
4. SH Golden , JE Williams , DE Ford , . Depressive symptoms and the risk of type 2 diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care. 2004; 27(2): 429–435.
5. BS Jonas , P Franks , DD Ingram . Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-Up Study. Arch Fam Med. 1997; 6(1): 43–49.
6. SL Larson , PL Owens , D Ford , W Eaton . Depressive disorder, dysthymia, and risk of stroke: thirteen-year follow-up from the Baltimore epidemiologic catchment area study. Stroke. 2001; 32(9): 1979–1983.
7. JC Nelson . The STAR*D study: a four-course meal that leaves us wanting more. Am J Psychiatry. 2006; 163(11): 1864–1866.
8. AJ Rush , MH Trivedi , SR Wisniewski , . Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163(11): 1905–1917.
9. WH Crown , S Finkelstein , ER Berndt , . The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002; 63(11): 963–971.
10. RC Shelton , O Osuntokun , AN Heinloth , SA Corya . Therapeutic options for treatment-resistant depression. CNS Drugs. 2010; 24(2): 131–161.
12. JH Meyer , N Ginovart , A Boovariwala , . Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006; 63(11): 1209–1216.
13. JH Meyer , AA Wilson , S Sagrati , . Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry. 2009; 66(12): 1304–1312.
14. S Johnson , CA Stockmeier , JH Meyer , . The reduction of r1, a novel repressor protein for monoamine oxidase a, in major depressive disorder. Neuropsychopharmacology. 2011; 36(10): 2139–2148.
17. EE Billett . Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicology. 2004; 25(1–2): 139–148.
18. F Lotufo-Neto , M Trivedi , ME Thase . Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999; 20(3): 226–247.
20. M Wimbiscus , O Kostenko , D Malone . MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med. 2010; 77(12): 859–882.
22. J Elis , DR Laurence , H Mattie , BN Prichard . Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure. Br Med J. 1967; 2(5544): 75–78.
23. AJ Boakes , DR Laurence , PC Teoh , . Interactions between sympathomimetic amines and antidepressant agents in man. Br Med J. 1973; 1(5849): 311–315.
25. JA Yagiela , SR Duffin , LM Hunt . Drug interactions and vasoconstrictors used in local anesthetic solutions. Oral Surg Oral Med Oral Pathol. 1985; 59(6): 565–571.
26. DG Wells , AR Bjorksten . Monoamine oxidase inhibitors revisited. Can J Anaesth. 1989; 36(1): 64–74.
27. C Sun-Edelstein , SJ Tepper , RE Shapiro . Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf. 2008; 7(5): 587–596.
28. SE Hilton , H Maradit , HJ Moller . Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur Arch Psychiatry Clin Neurosci. 1997; 247(3): 113–119.
30. CB Raymond , SG Morgan , PA Caetano . Antidepressant utilization in British Columbia from 1996 to 2004: increasing prevalence but not incidence. Psychiatr Serv. 2007; 58(1): 79–84.
31. SU Karkare , S Bhattacharjee , P Kamble , R Aparasu . Prevalence and predictors of antidepressant prescribing in nursing home residents in the United States. Am J Geriatr Pharmacother. 2011; 9(2): 109–119.
32. KI Shulman , HD Fischer , N Herrmann , . Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults. J Clin Psychiatry. 2009; 70(12): 1681–1686.
33. C Coupland , P Dhiman , G Barton , . A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technol Assess. 2011; 15(28): 1–202.
34. JS Fowler , J Logan , AJ Azzaro , . Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010; 35(3): 623–631.
35. CM VanDenBerg , LF Blob , EM Kemper , AJ Azzaro . Tyramine pharmacokinetics and reduced bioavailability with food. J Clin Pharmacol. 2003; 43(6): 604–609.
37. AJ Azzaro , CM Vandenberg , LF Blob , . Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. J Clin Pharmacol. 2006; 46(8): 933–944.